| Biomarker ID | 1121 |
| PMID | 23716368 |
| Year | 2013 |
| Biomarker | Asporin; Cartilage oligomeric matrix Protein (COMP); Versican; EMILIN 3; |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Agressive Prostate Cancer (Fold Change); [Asporin (2.14 fold); Cartilage oligomeric matrix Protein (COMP) (100 fold) ; Versican (100 fold) ; EMILIN 3 ( 6 fold); |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Agressive Vs Non Agressive Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | Verification Set: 12 Samples from Normal Prostate, 31 from Non Agressive Prostate Cancer and 24 Agressive Prostate Cancer set were chosen for analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Asporin (p=0.00016) ; Cartilage oligomeric matrix Protein (COMP) (p = 0.00228) ; Versican ( 0.03367) ; EMILIN 3 (0.04983); |
| Method Used | Liquid chromatography–mass spectrometry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |